Klinger Shannon Thyme sold $174K of MRNA

The FDA approved new COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax-Sanofi for 2026-27, targeting current variants. Moderna received approval for two vaccines. Distribution will be limited to specific age groups and high-risk individuals, with availability expected in the fall.

Moderna (MRNA) and BioNTech (BNTX) are focusing on cancer vaccines post-pandemic. Moderna's cancer vaccine showed strong Phase 3 results, boosting its shares. BioNTech's pumitamig, in development with Bristol Myers Squibb, aims to challenge Merck's Keytruda. BioNTech's market cap is $26B, while Moderna's is $60B. Both are valued on pipeline progress, with Moderna offering near-term certainty and BioNTech potential upside if pumitamig succeeds.

Moderna (MRNA) shares fell 2.9% after a Rothschild & Co analyst downgraded the stock to Sell, citing valuation concerns. The analyst raised the price target to $81, implying a 46% downside from the previous close of $150.81. This follows positive Phase 3 trial results for Moderna's cancer vaccine candidate, though the analyst deemed the market's reaction overexuberant. The stock later recovered slightly to $146.24.

Tyson Foods fell 7% after cutting fiscal 2026 guidance. Meta rose 3% on AI model launch. Dell gained 5% post-earnings. Crypto-related stocks climbed with bitcoin. Robinhood jumped 15% on Deutsche Bank's report. Ciena dropped 9% despite beating estimates. Tesla advanced 6% ahead of Cybercab event. Snowflake surged 22% on strong earnings. HPE slipped 4% with lower-than-expected growth forecast. Broadcom lost 3% on weak revenue outlook. Campbell's fell 9% on lagging guidance. Ultragenyx plunged 44%

Snowflake shares surged 24% after Q2 results beat estimates, with revenue of $1.55B and EPS of $0.62. Broadcom fell 2.5% on lower Q4 revenue forecasts. Campbell's dropped 7% on weak fiscal 2027 guidance. Ultragenyx plunged 46% after a failed drug trial. Petco rose 9% on strong Q2 margins. Moderna declined 2% after a downgrade. Argan gained 7.5% on better-than-expected earnings. Five Below rose 4.5% on strong Q2 results. Victoria's Secret fell 18% on missed revenue estimates. Netskope rose 12% on

The FDA approved updated COVID-19 vaccines from Moderna, Pfizer, and Sanofi for the fall season. Health insurers, per AHIP, will cover these vaccines, as required by the Affordable Care Act. Uninsured individuals may access free vaccines through state or federal programs. The vaccines target specific high-risk groups, with recommendations from the AAFP and CDC.